Skip to main content
Top
Published in: Tumor Biology 11/2016

01-11-2016 | Original Article

Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients

Authors: Xiaofeng Hang, Zhiqin Wu, Kaijian Chu, Guanzhen Yu, Haoran Peng, Haiguang Xin, Xiaohui Miao, Junxue Wang, Wensheng Xu

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

The aim of this study was to investigate the prognostic value of dicarbonyl/L-xylulose reductase (DCXR) in human hepatocellular carcinoma (HCC). Immunohistochemistry and tissue microarrays were used to evaluate DCXR protein expression levels. Image-Pro Plus was used to calculate the integral optic density (IOD) in each tissue sample, which represented the expression level of DCXR. DCXR proteins were found to be significantly lower in HCC tumor tissues (P < 0.0001) according to immunohistochemical analysis of DCXR protein levels in 74 paired HCC tissue and peritumoral non-cancer tissues. The prognostic value of DCXR in HCC was assessed in 290 cases of the training cohort and 74 cases of the validation cohort. Shorter overall survival (OS) time and shorter time to recurrence (TTR) in both the training and validation set were found to be associated with lower expression levels of DCXR. In the training set, the expression level of DCXR in HCC was an independent prognostic factor for OS according to univariate and multivariate analyses. In conclusion, DCXR expression is an independent prognostic factor for OS and TTR of post-operative HCC patients, and low expression levels of DCXR in HCC may indicate poor outcome of HCC patients after surgical resection.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–17.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–17.CrossRefPubMed
2.
3.
go back to reference YF X, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, et al. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J Hepatol. 2010;53:872–9.CrossRef YF X, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, et al. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J Hepatol. 2010;53:872–9.CrossRef
5.
go back to reference Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003–21.CrossRefPubMedPubMedCentral Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003–21.CrossRefPubMedPubMedCentral
6.
go back to reference Nakagawa J, Ishikura S, Asami J, Isaji T, Usami N, Hara A, et al. Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney. J Biol Chem. 2002;277:17883–91.CrossRefPubMed Nakagawa J, Ishikura S, Asami J, Isaji T, Usami N, Hara A, et al. Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney. J Biol Chem. 2002;277:17883–91.CrossRefPubMed
7.
go back to reference Cho-Vega JH, Tsavachidis S, Do KA, Nakagawa J, Medeiros LJ, McDonnell TJ. Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomark Prev. 2007;16:2615–22.CrossRef Cho-Vega JH, Tsavachidis S, Do KA, Nakagawa J, Medeiros LJ, McDonnell TJ. Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomark Prev. 2007;16:2615–22.CrossRef
8.
go back to reference Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P, et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteome. 2014;106:99–112.CrossRef Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P, et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteome. 2014;106:99–112.CrossRef
9.
go back to reference Jin GZ, WL Y, Dong H, Zhou WP, YJ G, Yu H, et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 2013;59:510–7.CrossRefPubMed Jin GZ, WL Y, Dong H, Zhou WP, YJ G, Yu H, et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 2013;59:510–7.CrossRefPubMed
10.
go back to reference Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, et al. A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour Biol. 2013;34:2183–8.CrossRefPubMed Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, et al. A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour Biol. 2013;34:2183–8.CrossRefPubMed
11.
go back to reference Tan N, Liu Q, Liu X, Gong Z, Zeng Y, Pan G, et al. Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis. Histopathology. 2016;68:221–9.CrossRefPubMed Tan N, Liu Q, Liu X, Gong Z, Zeng Y, Pan G, et al. Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis. Histopathology. 2016;68:221–9.CrossRefPubMed
12.
go back to reference Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMed Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMed
13.
go back to reference Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res Treat. 2015;47:853–61.CrossRefPubMedPubMedCentral Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res Treat. 2015;47:853–61.CrossRefPubMedPubMedCentral
14.
go back to reference Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21:3928–35.CrossRefPubMedPubMedCentral Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21:3928–35.CrossRefPubMedPubMedCentral
15.
go back to reference Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.CrossRefPubMed Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.CrossRefPubMed
16.
go back to reference San Miguel C, Fundora Y, Triguero J, Muffak K, Villegas T, Becerra A, et al. Immunosuppression strategies in the treatment of hepatocellular carcinoma in Virgen de las Nieves university hospital. Transplant Proc. 2015;47:2371–3.CrossRefPubMed San Miguel C, Fundora Y, Triguero J, Muffak K, Villegas T, Becerra A, et al. Immunosuppression strategies in the treatment of hepatocellular carcinoma in Virgen de las Nieves university hospital. Transplant Proc. 2015;47:2371–3.CrossRefPubMed
17.
go back to reference Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res. 2009;15:5518–27.CrossRefPubMed Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res. 2009;15:5518–27.CrossRefPubMed
18.
go back to reference El-Kabbani O, Ishikura S, Darmanin C, Carbone V, Chung RP, Usami N, et al. Crystal structure of human L-xylulose reductase holoenzyme: probing the role of Asn107 with site-directed mutagenesis. Proteins. 2004;55:724–32.CrossRefPubMed El-Kabbani O, Ishikura S, Darmanin C, Carbone V, Chung RP, Usami N, et al. Crystal structure of human L-xylulose reductase holoenzyme: probing the role of Asn107 with site-directed mutagenesis. Proteins. 2004;55:724–32.CrossRefPubMed
19.
go back to reference Matsunaga T, Kamiya T, Sumi D, Kumagai Y, Kalyanaraman B, Hara A. L-xylulose reductase is involved in 9,10-phenanthrenequinone-induced apoptosis in human T lymphoma cells. Free Radic Biol Med. 2008;44:1191–202.CrossRefPubMed Matsunaga T, Kamiya T, Sumi D, Kumagai Y, Kalyanaraman B, Hara A. L-xylulose reductase is involved in 9,10-phenanthrenequinone-induced apoptosis in human T lymphoma cells. Free Radic Biol Med. 2008;44:1191–202.CrossRefPubMed
20.
go back to reference Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21:401–16.CrossRefPubMedPubMedCentral Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21:401–16.CrossRefPubMedPubMedCentral
21.
go back to reference Niu J, Lin Y, Guo Z, Niu M, Su C. The epidemiological investigation on the risk factors of hepatocellular carcinoma: a case-control study in Southeast China. Medicine (Baltimore). 2016;95:e2758.CrossRef Niu J, Lin Y, Guo Z, Niu M, Su C. The epidemiological investigation on the risk factors of hepatocellular carcinoma: a case-control study in Southeast China. Medicine (Baltimore). 2016;95:e2758.CrossRef
Metadata
Title
Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients
Authors
Xiaofeng Hang
Zhiqin Wu
Kaijian Chu
Guanzhen Yu
Haoran Peng
Haiguang Xin
Xiaohui Miao
Junxue Wang
Wensheng Xu
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5302-9

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine